JW중외제약

001060KOSPI

57.0 / 100

Reference Date: 2026-10-23

Financial Score29.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 10.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Chungwa Pharmaceutical focuses on the research, development, manufacturing, and sales of pharmaceuticals, leveraging a strong pipeline of original drugs such as Rivaro and Winnerf, along with a global R&D network. The company offers a diverse range of specialty and over-the-counter medications, as well as healthcare products, maintaining a competitive edge in both domestic and international markets.

Number of Employees

1,106people

Average Salary

64.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.61Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

1.54Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

17.60Industry Average 8.007.0Point

2.2x industry avg (excellent)

Debt Ratio

7.24Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼1.6% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 18.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 24,350Won52-week high 39,05052-week low 22,000

1-month return1.0Point

1m -10.81% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral[기재정정]벌금등의부과2026-10-08
Neutral타법인주식및출자증권취득결정2026-09-29